Anti-Obesity Activity of Red Ginseng Acidic Polysaccharide from Korean Red Ginseng (Panax ginseng C.A. Meyer)

Yi-Seong Kwak*, Jong-Soo Kyung and Jae-Joon Wee

The Korean Ginseng Research Institute, South Korea

Abstract

Objectives: The present study investigated the anti-obesity activities of red ginseng acidic polysaccharide (RGAP) from Korean red ginseng (Panax ginseng C.A. Meyer) in high-fat diet (HFD)-induced mice.

Methods: Forty mice were divided randomly into four groups (n=10, respectively): normal control (NC), high-fat-diet (HFD), HFD plus RGAP300mg/kg, HFD plus RGAP500mg/kg. The normal control was fed a normal diet and the other groups were fed an HFD. HFD mice were made obese by high-fat diet (35% fat) feeding for 6 weeks. The test mice were given red ginseng acidic polysaccharide orally at a single dose per day. Body weights of the mice were measured at weekly intervals. The effects of RGAP on obesity functions were assessed by measuring the serum lipid profiles and biomarkers of obesity. In addition, abdominal fat volumes were measured at the end of the experiment by using Micro X-ray CT.

Results: Mice in the HFD group showed an increase in body weight and food efficiency ratio, which means body weight gain per food intake. However, RGAP significantly reduced these values when compared with the normal control group. The RGAP group also showed significantly decreased epididymal fat mass. An increase in the serum levels of triglyceride and LDL/HDL ratio were observed in the HFD group, but RGAP administration reduced these serum levels. Serum levels of hepatic function markers such as AST and ALT, which were elevated by HFD-feeding, were also significantly reduced in the RGAP group. Levels of leptin, adiponectin, and lipoprotein lipase (LPL), which regulate glucose and lipid metabolism, were impaired by HFD. RGAP brought these levels back to near normal levels. In addition, it was confirmed by Micro X-ray CT that the abdominal fat masses increased by the HFD were reduced by RGAP.

Conclusion: This study showed that RGAP protected mice from obesity in the HFD-fed group. RGAP exerts anti-obesity effects in mice via the activation of lipoprotein lipase and improvement of leptin and adiponectin, which carry out critical functions in energy and lipid metabolism. These results suggest that red ginseng acidic polysaccharide might be a preventative functional food for these metabolic disorders.

Keywords: Panax ginseng C.A. Meyer; Red ginseng acidic polysaccharide; High-fat diet; Anti-obesity; Lipoprotein lipase; Abdominal fat mass; Micro X-ray CT

Abbreviations: HFD: High-Fat Diet; RGAP: Red Ginseng Acidic Polysaccharide; LDL: Low-Density Lipoprotein Cholesterol; HDL: High-Density Lipoprotein Cholesterol; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; LPL: Lipoprotein Lipase

Introduction

Korean ginseng (Panax ginseng C.A. Meyer) has been known to be a valuable food and has been traditionally used as an important herbal medicine in East Asian countries including Korea, China, and Japan for thousands of years. The ginseng root is traditionally used as an adaptogen as it is stated to have the capacity to normalize body functions and strengthen systems that are compromised by stress [1]. Adaptogens are reported to have a protective effect on health against a wide variety of environmental assaults and emotional conditions [2-5]. Fresh ginseng degrades easily at room temperature. Consequently, ginseng is processed into red ginseng through the process of steaming. The steaming and drying ginseng undergoes to become red ginseng produces changes to its chemical profile. Red ginseng and ginseng are individually regulated in Korea, Japan, and China. It has been reported that ginseng and red ginseng have similar biological effects because they come from the same part of the plant but are processed differently [1].

The main biological activities of Korean red ginseng are known to include enhancement effects such as the recovery of vital energy as well as the alleviation of fatigue, blood flow...
improvement, antioxidative effects, memory enhancement, and the alleviation of menopausal disorder [6-10], as well as a positive effect on antihyperlipidemic disorder [11]. The effects of ginseng on obesity have also been reported [12,13]. Panax ginseng is indeed being widely used to treat numerous diseases such as cancer, diabetes, and cardiovascular diseases [14]. Active constituents with curative features found in most ginseng species include ginsenosides, polysaccharides, peptides, polyacetylenic alcohols, and fatty acids [15]. Of these, ginsenosides, a group of saponins with a triterpenoid dammarane structure, have been studied as ginseng’s primary pharmacological components with a variety of effects such as anti-diabetic, anti-cancer, anti-inflammatory, anti-hyperlipidemic, and anti-atherosclerosis activities [15,16].

Polysaccharide fractions from ginseng, which is its second major active component, have also been explored to understand ginseng’s biological roles in pharmacology in terms of immunostimulatory functions [15]. Numerous studies have revealed that polysaccharides from Panax ginseng have mitogenic activities, anti-tumor activities, and immunostimulating activities in cydorphosphate-treated immunosuppressed mice [15,17-19]. Polysaccharides are compounds consisting of numerous monosaccharides and have molecular weights ranging from tens to thousands. Polysaccharides have recently been shown to have various physiological activities. Among them, Panaxan A-U (21 kinds) [20], which has defense mechanisms, and polysaccharides with anti-complementary properties [21] have been isolated from Korean ginseng. It has also been reported that red ginseng acidic polysaccharide (RGAP) from Korean red ginseng was able to up-regulate immunostimulating and anti-tumor activities for the activation of natural killer cells and nitric oxide production in macrophages and in tumor-bearing models [22,23]. RGAP has been known as an immunostimulator and anti-tumor activator. Recently, it was also reported that RGAP plays a role in reducing hyperlipidemic conditions in both exogenous and endogenous short-term animal models [11]. It has also been reported that acidic polysaccharides inhibit the activity of toxohormone-L, one of the toxins that accelerates lipolysis [24] and have medicinal effects of enhancing one’s immune status.

Obesity is a serious health problem that has become prevalent in developed countries in recent years and is a risk factor for metabolic disease [25]. Some studies of Korean ginseng and red ginseng on lipid metabolism such as hyperlipidemia and hypercholesterolemia have been also reported. In animal tests, saponins from ginseng block the absorption of fat and cholesterol, thereby promoting metabolism [26,27]. In a study on humans involving administration of red ginseng for 4 weeks, body fat was decreased. A study conducted among obese women in their 20s also delivered a similar result. Korean red ginseng lowers total cholesterol, triglycerides, and low-density lipoprotein in blood and expedites the breaking down of body fat and is thus effective in preventing and treating hyperlipidemia [28]. Korean red ginseng attenuated hypercholesterolemia-enhanced platelet aggregation in high-cholesterol-diet-fed rabbits [29], and Korean red ginseng extract also showed hepato-protective effects which were associated with anti-obesity effects in mice fed a high-fat-diet (HFD).

Recently, many studies have focused on evaluating the effects of Panax ginseng on obesity, hyperlipidemia, and metabolic diseases. Ginseng saponin has been shown to exert anti-obesity effects in animal models fed an HFD via the inhibition of pancreatic lipase activity, leading to the reduction of intestinal absorption of dietary fat [30]. It has also been shown to regulate the hypothalamic expression of orexigenic neuropeptide Y and anorexigenic cholecystokinin in HFD groups [31]. The alteration of lipid profiles such as triglyceride and cholesterol were reversed by ginseng treatment in hyperlipidemic animals with the activation of lipoprotein lipase [32]. Several studies on the anti-obesity effects of ginseng have also been conducted at the molecular level; ginsenoside-Rh2 and ginsenoside-Rg3 effectively inhibited adipocyte differentiation via peroxisome proliferator-activated receptor (PPAR)-y inhibition and adenosine monophosphate-activated protein kinase (AMPK) activation. The results suggested that ginsenoside-Rh2 and ginsenoside-Rg3 might contribute to the anti-obesity effect of ginseng via the regulation of PPAR-y and AMPK signaling [29,33]. Ginsenoside-Re has shown anti-hyperlipidemic effects in mice fed an HFD with antioxidant effects as one of its action mechanisms [34].

Regarding the non-saponin component, it has been reported that non-saponin fractions containing polysaccharide are capable of inhibiting epinephrine-induced lipolysis and of stimulating insulin-mediated lipogenesis from glucose in rat adipocytes. Polysaccharides from Korean ginseng were found to inhibit toxohormone L-induced lipolysis [33]. Polysaccharides from Korean red ginseng modulated pancreatic lipase activity and caused a reduction of plasma triglyceride levels, implying the involvement of pancreatic lipase in the reduction of lipolysis [34]. In another study, Korean red ginseng polysaccharide significantly reduced triglycerides in both exogenous and endogenous short-term animal models via lipoprotein lipase activation [11].

Although several reports have indicated the role of ginseng saponin on lipid metabolism and hyperlipidemia in vivo, the effect of red ginseng polysaccharide on lipid metabolism in high obesity conditions induced by an HFD has not been elucidated yet. In this study, therefore, we aimed to explore the anti-obesity effect of red ginseng acidic polysaccharide in HFD-fed mice.

Material and Methods
Preparation of red ginseng acidic polysaccharide (RGAP)

RGAP was isolated from Korean red ginseng as described previously [35]. Briefly, Korean red ginseng powder was percolated with 5 volumes of 70% ethanol to extract ethanol-soluble materials. Remaining residues were then percolated with 5 volumes of distilled water, and the resulting water-soluble fractions were concentrated by vacuum evaporation. The concentrates underwent ultrafiltration to completely cut off small molecules less than 10kDa (Ultrafiltration kit, Millipore, Pellicone 2, Bedford, M.A, USA) and to obtain the non-ultrafiltrated fraction consisting of
acidic polysaccharide (yield: about 15%). One milligram of RGAP contained less than 0.006EU of endotoxin [11].

**Animals and diets**

Specific pathogen-free mice (ICR, male, 5 week, 25±2g) were purchased from Charles River Laboratories, Japan and maintained in a temperature and humidity-controlled room on a 12-hour light-dark cycle. The mice were permitted to acclimate to the facility for one week and were housed at two heads per cage with ad libitum access to food and water. The forty mice were divided randomly into four groups (n=10, respectively): normal control (NC), high-fat-diet (HFD), HFD plus RGAP 300mg/kg, and HFD plus RGAP 500mg/kg. The normal group was fed a normal diet (AIN-76A), and the other groups were fed an HFD. The normal diet contained 3,902 kcal, whereas the HFD contained 5,592kcal and 35% fat (Table 1). The normal diet (AIN-76A) and HFD diet were custom-formulated by Feed Lab Korea Co., Ltd (Hanam, Gyeonggi, Korea). The mice received the experimental diets for 6 weeks, and RGAP groups (R300, R500) received a dose of 300mg/kg/day and 500mg/kg/day, respectively.

**Body weight and food intake**

Body weights were measured once per week, and food intake was recorded every three days. The results of body weight and food intake are shown in Figure 1 and Table 2.

![Figure 1: Effect of RGAP on body weight in HFD-fed mice.](image)

NC: Normal Control; HFD: High-Fat Diet group; R300: HFD+RGAP300mg/kg group; R500: HFD+RGAP500mg/kg group; #significant p<0.05: HFD vs R500

### Table 1: Composition of experimental diets.

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Normal Diet (AIN-76A)</th>
<th>HFD (high-fat-diet) (Units: g/kg diet)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casein</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>DL-Methionine</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Corn starch</td>
<td>150</td>
<td>150</td>
</tr>
<tr>
<td>Sucrose</td>
<td>500</td>
<td>116</td>
</tr>
<tr>
<td>Cellulose</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Corn oil</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Beef tallow</td>
<td>-</td>
<td>350</td>
</tr>
<tr>
<td>AIN-76 Mineral mixture</td>
<td>35</td>
<td>50</td>
</tr>
<tr>
<td>AIN-76 Vitamin mixture</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td>Choline bitarate</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>Na-Cholate</td>
<td>-</td>
<td>5</td>
</tr>
<tr>
<td>Total amounts</td>
<td>1,000</td>
<td>1,000</td>
</tr>
<tr>
<td>Kcal</td>
<td>3,902kcal</td>
<td>5,592kcal</td>
</tr>
</tbody>
</table>
Micro X-ray CT (computed tomography) analysis

The mice were subjected to micro X-ray CT imaging (DRGEM, Harmony 130G, Korea). Tube voltage was set at 130kV, and the mice were scanned with a rotating beam (cone beam CT method). Micro X-ray CT is a non-destructive technique that allows visualization of the internal structure of mice, determined mainly by variations in density and atomic composition. This is followed by the reconstruction of two-dimensional cross-sections perpendicular to the axis of rotation [36]. The Micro X-ray CT was carried out on three mice in each group. Abdominal fat mass in mice were represented as percent of image area. The area percent was analyzed by computer area analysis between groups.

Organ weight and lipid concentrations

At the end of the feeding period, the mice were placed on overnight fasting. After collecting the blood sample, the epididymal fat, liver, and other organs were immediately excised and weighed. Blood was extracted from the heart and centrifuged for 10min at 3000 x g. All serum was stored at -70 °C until assayed for the biological parameters. The total cholesterol (TC), triglyceride (TG), aminotransferase (AST), alanine aminotransferase (ALT), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) were measured using commercial kits from Wako (Japan) using a Hitachi 7020 analyzer. The serum leptin and adiponectin concentrations were determined with an ELISA kit (R&D Systems, Inc., Minneapolis, MN, USA).

LPL activity assay

LPL activity (lipoprotein lipase) was measured from plasma

<table>
<thead>
<tr>
<th>Group</th>
<th>Body weight (g)</th>
<th>Body weight gain (g/6 weeks)</th>
<th>Food intake (g/ day)</th>
<th>Food efficiency ratio^1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial</td>
<td>Final</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NC</td>
<td>25.0±1.2</td>
<td>39.2±1.0</td>
<td>14.2±0.9</td>
<td>0.48±0.03</td>
</tr>
<tr>
<td>HFD</td>
<td>24.7±1.1</td>
<td>45.6±2.2*</td>
<td>20.9±2.5**</td>
<td>0.46±0.07</td>
</tr>
<tr>
<td>R300</td>
<td>25.0±1.2</td>
<td>43.4±1.1</td>
<td>18.4±1.8</td>
<td>0.48±0.04</td>
</tr>
<tr>
<td>R500</td>
<td>26.4±1.0</td>
<td>42.9±1.5*</td>
<td>16.5±1.4**</td>
<td>0.48±0.03</td>
</tr>
</tbody>
</table>

Food efficiency ratio= [Body weight gain(g)/Food intake(g)]

*, ** -significant p<0.05, p<0.01: normal control vs HFD group, R300 or R500 group

#, ## -significant p<0.05, p<0.01: HFD group vs R300 or R500 group

Micro X-ray CT analysis

The results of the micro X-ray CT scanning are shown as Figure 2. X-ray CT images showed the positive effect of RGAP on abdominal fat accumulation in mice. The abdominal fat area percent represented in the X-ray CT images was obtained by calculating the area ratio. The abdominal fat mass of X-ray CT in the HFD alone group showed an increase of 18.9% when compared with the NC group. However, HFD plus RGAP 300mg/kg (R300) and HFD plus RGAP 500mg/kg (R500) reduced the increase by 5.4% and 11.1%, respectively, when compared to the HFD group alone.
Organ weight, epididymal fat weight and hepatic enzyme

The changes of organ weights, epididymal fat and hepatic enzyme are shown in Table 3. The mice fed the HFD had significantly higher liver weight than that of the mice fed the normal diet (NC). The liver weights in the HFD group increased 10.7% more than that of normal control, but liver weights in the HFD plus RGAP groups (R300, R500) reduced the HFD-induced increase in the weights by 4.8% and 5.5%, respectively. The weights of other organ such as the spleen and kidney did not change between treatment groups. On the other hand, the values of AST and ALT in the HFD group were higher than those in the NC. Administration with RGAP (R300, R500) reduced these values significantly, with \( p < 0.05 \). These results indicated that HFD feeding in ICR mice for 6 weeks eventually induced obesity parameters such as epididymal fat, liver weight, and hepatic enzymes, and that RGAP effectively prevented HFD-induced obesity. The epididymal fat weight was significantly increased by 18.8% in the HFD group when compared with the NC, but RGAP administration inhibited the epididymal fat deposition, as shown in Figure 3. The epididymal fat weight in the HFD plus RGAP groups (R300, R500) was reduced by 3.6% and 8.5%, respectively, when compared with the HFD group alone.

Figure 2: Micro X-ray CT images of abdominal fat mass in HFD-fed mice.
NC: Normal Control; HFD: high-fat diet group; R300: HFD+RGAP300mg/kg group; R500: HFD+RGAP500mg/kg group

Figure 3: Effect of RGAP on epididymal fat weight in HFD-fed mice.
NC: Normal Control; HFD: High Fat Diet group; R300: HFD+RGAP300mg/kg group; R500: HFD+RGAP500mg/kg group; \(*\)significant \( p < 0.05 \): NC vs HFD; \#significant \( p < 0.05 \): HFD vs R500
**Table 3:** Effect of RGAP on organ weight and liver-related enzyme values in HFD-fed mice.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Liver (g)</th>
<th>Spleen (g)</th>
<th>Kidney (g)</th>
<th>AST (mg/dl)</th>
<th>ALT (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NC</td>
<td>1.31±0.13</td>
<td>0.12±0.02</td>
<td>0.53±0.07</td>
<td>132.4±73.4</td>
<td>23.9±3.41</td>
</tr>
<tr>
<td>HFD</td>
<td>1.45±0.12¥</td>
<td>0.14±0.04</td>
<td>0.56±0.06</td>
<td>150.9±43.4*</td>
<td>25.1±1.30*</td>
</tr>
<tr>
<td>R300</td>
<td>1.38±0.20</td>
<td>0.14±0.06</td>
<td>0.54±0.06</td>
<td>139.3±35.2</td>
<td>24.4±2.07</td>
</tr>
<tr>
<td>R500</td>
<td>1.37±0.20</td>
<td>0.13±0.04</td>
<td>0.51±0.05</td>
<td>135.0±66.3#</td>
<td>22.3±2.66#</td>
</tr>
</tbody>
</table>

NC: Normal Control; HFD: High Fat Diet Group; R300: HFD+RGAP 300mg/kg group; RGAP500: HFD+RGAP 500mg/kg group; ¥significant p<0.05: NC vs HFD; #significant p<0.05: HFD vs R300 or R500

**Lipid concentrations**

The levels of triglyceride (TG) and LDL in the HFD group were higher than in the NC group, but total cholesterol (TC) and HDL levels were lower. When RGAP was administered, the TG and HDL parameters were recovered, but neither TC nor LDL changed significantly. The TG level in the HFD group was increased 26.0%, but those of the HFD plus RGAP groups (R300, R500) were significantly reduced by 4.5% and 8.3% when compared with the HFD group, respectively. Conversely, the HDL level in the HFD group decreased by 18.8%, but those of the HFD plus RGAP groups (R300, R500) significantly recovered by 15.3% and 16.2%, respectively, when compared with the HFD group. The ratio of LDL/HDL also increased 76.2% in the HFD group, but RGAP administration (R300, R500) reduced this by 16.2% and 42.3%, respectively, when compared with the HFD group (Table 4). RGAP significantly suppressed increases in the TG level and recovered the reduction of HDL. However, RGAP did not alter the levels of TC and LDL. HFD not only elevated serum leptin content but also lowered adiponectin. RGAP administration reversed the rise in leptin and decrease in adiponectin, which are associated with energy expenditure and fatty acid oxidation. The leptin content in the HFD group increased 171.4%, but those of the HFD plus RGAP groups (R300, R500) dropped by 5.3% and 15.8%, respectively, when compared with the HFD group (Figure 4). The adiponectin content in the HFD group decreased 55.6%, but the HFD plus RGAP groups (R300, R500) showed an increase of 50% and 100%, respectively (Figure 5).

**Table 4:** Effect of RGAP on serum triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) contents in HFD-fed mice.

<table>
<thead>
<tr>
<th>Group</th>
<th>TG (mg/dl)</th>
<th>TC (mg/dl)</th>
<th>LDL (mg/dl)</th>
<th>HDL (mg/dl)</th>
<th>LDL/HDL ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>NC</td>
<td>183.6±53.1</td>
<td>190.9±23.2</td>
<td>17.3±11.9</td>
<td>80.8±7.3</td>
<td>0.21</td>
</tr>
<tr>
<td>HFD</td>
<td>231.3±18.9*</td>
<td>158.9±39.1</td>
<td>24.5±20.3</td>
<td>66.0±13.8</td>
<td>0.37</td>
</tr>
<tr>
<td>R300</td>
<td>221.0±40.8#</td>
<td>159.0±53.5</td>
<td>23.9±4.5</td>
<td>76.1±18.8#</td>
<td>0.31</td>
</tr>
<tr>
<td>R500</td>
<td>212.3±34.1*,#</td>
<td>160.6±30.1</td>
<td>21.6±10.0</td>
<td>76.7±27.5#</td>
<td>0.28#</td>
</tr>
</tbody>
</table>

NC: Normal Control, HFD: High-Fat Diet Group, R300: HFD+RGAP 300mg/kg group, R500: HFD+RGAP500mg/kg group; ¥significant p<0.05: NC vs HFD; #significant p<0.05: HFD vs R300 or R500
Figure 5: Effect of RGAP on serum adiponectin in HFD-fed mice.

NC: Normal Control; HFD: High Fat Diet Group; R300: HFD+RGAP300mg/kg group, R500: HFD+RGAP500mg/kg group; #significant p<0.05: HFD vs R300 or R500

LPL Activity

Since it is known that LPL (lipoprotein lipase) is a key atheroprotective enzyme [37] in regulating plasma TG levels by removing TG-rich lipoproteins from circulating plasma [5,38]. We investigated whether RGAP is able to modulate to explain its anti-obesity and anti-hyperlipidemic activity with hypoglycemic action due to HFD administration. Interestingly, Figure 6 showed lower LPL activity in the HFD group when compared with the NC group. Orally administered RGAP (R300, R500) dose-dependently up-regulated LPL activity by 47.1% and 83.9%, respectively at p<0.05, when compared to the HFD.

Figure 6: Effect of RGAP on serum adiponectin in HFD-fed mice.

NC: Normal Control; HFD: High Fat Diet Group; R300: HFD+RGAP300mg/kg group, R500: HFD+RGAP500mg/kg group; #significant p<0.05: HFD vs R300 or R500

Discussion

We found that RGAP administration reduced the levels of both obesity and hyperlipidemia, indicating that RGAP may diminish the levels of TG through the activation of LPL. Similar results were found with other polysaccharides such as Auricularia auricular-derived polysaccharides and fucoidan [38,39]. Therefore, these results suggest that the administration of RGAP in mice may modulate obese conditions by upregulating the degradation enzyme LPL activity. LPL is most abundantly expressed in adipose tissue, macrophages, heart, and skeletal muscle, where it acts as a gatekeeper for the entry of fatty acids into tissue [40-43]. LPL controls systemic lipid partitioning, which is essential for energy homeostasis of the body [44]. Other factors also seem to be involved in the regulation of LPL activity. It has been suggested that the binding between LPL and heparan sulfate proteoglycans plays a critical role in LPL function [40]. However, more research is needed to prove its action mode and another factors. Considering that the higher molecular weight β-glucan is clinically effective in controlling blood lipid composition [41], it is suggested that the anti-obesity activity of RGAP seems to be available in the human body, although its anti-obesity efficacy was seen at higher doses. Whether RGAP can be developed to be functional food with anti-obesity properties will be examined in next trial. The analysis of component sugars in RGAP by HPLC revealed that the acidic sugars contained galacturonic acid as a major component and glucuronic...
Our previous report has shown that the decrease of TC, but influenced TG selectively, which is in line with our previous administration. Conversely, TC levels were significantly decreased LPL, which is a well-known enzyme that breaks down TG. In further reducing mechanism.

In this study, feeding mice an HFD for 6 weeks resulted in the development of obesity with hepatic injury or dysfunction. HFD-feeding also induced higher abdominal fat deposition and increased body weight. Although food consumption was not changed in the HFD-fed group, the increased caloric density of the HFD led to significantly higher weight gain compared with the normal diet group, resulting in higher food efficiency. Thus HFD-fed mice showed more rapid body weight gain and greater epididymal fat mass than those of mice fed a normal diet. However, the higher body weight gain and food efficiency exhibited in the HFD-fed group were reduced in the RGAP administration groups, which parallels the results obtained by Song et al. [43]. HFD feeding elevated the levels of serum TG and reduced the level of LDL in mice. However, the TG increase was reduced, and the HDL drop was elevated by RGAP administration, indicating that RGAP improves HFD-induced metabolic abnormalities. Micro X-ray CT is a non-destructive technique that allows visualization of the internal structure of mice, determined mainly by variations in density and atomic composition. This is followed by the reconstruction of two-dimensional cross-sections perpendicular to the axis of rotation [40]. Findings from our micro X-ray CT images suggest a positive effect of RGAP on abdominal fat accumulation in mice. In this study, we observed that RGAP administration reduced abdominal fat mass in HFD-fed mice. However, more research is needed to elucidate the reducing mechanism.

In previous studies, the activity and level of LPL recovered by RGAP administration in both endogenous and exogenous hyperlipidemic rat models has been demonstrated. TG was mainly decreased by LPL, which is a well-known enzyme that breaks down TG [45]. In this study, increased TG levels were significantly reduced by RGAP administration. Conversely, TC levels were significantly decreased in HFD-fed mice and were not changed by RGAP administration (Table 4). This indicates that RGAP administration did not affect the TC, but influenced TG selectively, which is in line with our previous results [11]. Our previous report has shown that the decrease of serum TG correlates with improved anti-hyperlipidemia in rats, but not with TC. Therefore, the decrease of TG levels associated with RGAP administration may be attributable to the decrease of epididymal fat (Figure 3). HFD-induced obesity, which is associated with abnormal biological metabolism, may be the cause of chronic metabolic diseases [46]. One of them is atherosclerosis, commonly referred to as a hardening or furring of the arteries. Atherosclerosis is induced by the formation of multiple plaques characterized by abnormal lipid metabolism within the arteries [47]. The RGAP-induced improvement in lipid profiles affected by the HFD-including TG, HDL-cholesterol, and LDL-cholesterol—suggests that it may enhance lipid metabolism and prevent obesity. Leptin, a regulator of energy homeostasis in both the central nervous system and the peripheral nerves, is an adipocyte-derived protein which functions as an adipocytokine and also senses and regulates body energy stores [48]. HFD-fed mice increased body weight and plasma leptin concentrations [49]. However, RGAP administration inhibited the rise of leptin concentration. On the other hand, adiponectin also is adipose tissue-specific protein that circulates in human plasma at high levels. It is one of the physiologically active polypeptides secreted by adipose tissue. Rise of adipose has been accompanied by a reduction in plasma glucose and increase in insulin sensitivity. Adiponectin increases insulin sensitivity by increasing tissue fat oxidation, resulting in reduced circulating fatty acid levels and reduced intracellular triglyceride contents in liver and muscle [48]. In the adipocytes of obesity, the expression of adiponectin was shown to be reduced as compared with normal models. Adiponectin depletion stimulates the secretion of free fatty acids on adipocytes. However, in this study, RGAP restored the abnormal or impaired levels of the important indicators-leptin and adiponectin—thus improving or delaying HFD-induced metabolic abnormalities. These results demonstrate that RGAP regulates imbalances of leptin and adiponectin, which result in metabolic disorder induced by HFD. Thereby, it indicates that RGAP can effectively improve HFD-induced impairments in obesity.

In this study, RGAP manifested dose-dependent effects on increases in body weight, epididymal fat weight, abdominal fat mass, and impaired serum biochemical parameters under HFD conditions. According to these results, we can conclude that RGAP regulates HFD-induced abnormal lipid metabolism via the modulation of the levels of leptin and adiponectin, thereby resulting in an anti-obesity effect. In conclusion, we found that RGAP recovered the levels leptin, adiponectin, and especially the level of TG through activation of LPL, suggesting that RGAP may improve obese-related conditions in metabolic syndromes. In future studies, the active components of RGAP obtained by molecular fractionation as well as the mechanisms relevant to the anti-obesity effects of RGAP in relation to lipid metabolism will be evaluated.

**Conclusion**

It can be concluded that red ginseng acidic polysaccharide from Korean red ginseng protected against both obesity and hyperlipidemia in high-fat diet mice models. Red ginseng acidic polysaccharide exerted anti-obesity effects in the animal models fed an HFD via the activation of lipoprotein lipase and the...
improvement of leptin and adiponectin, which carry out critical functions in energy and lipid metabolism. These results suggest that red ginseng acidic polysaccharide might be a preventative functional food for these metabolic disorders.

References


